Repurposing Ophthalmologic Timolol for Dermatologic Use: Caveats and Historical Review of Adverse Events

Yoon, Dokyoung; Kaur, Ramanjot; Gallegos, Anthony; West, Kaitlyn; Yang, Hsin-Ya; Schaefer, Saul; Tchanque-Fossuo, Catherine N.; Dahle, Sara E.; Isseroff, R. Rivkah

doi:10.1007/s40257-020-00567-3

Cited by 8 publications

(5 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The golden choice in the treatment of glaucoma is Timolol eye drops. Nevertheless, Timolol is recognized to reach the systemic circulation and cause different side effects [5]. While glaucoma is considered to be a serious chronic eye condition, there is still no perfect agent to be used for this disease, and there has been a constant urge for new drugs to be discovered [6].…”

Section: Introductionmentioning

confidence: 99%

The effect of Calcium channel blocker in the Betamethasone-induced Glaucoma model in rabbits

Abdulsahib¹,

Abood²

2021

J Adv Pharm Educ Res

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

The effect of Calcium channel blocker in the Betamethasone-induced Glaucoma model in rabbits

Abdulsahib¹,

Abood²

2021

J Adv Pharm Educ Res

View full text Add to dashboard Cite

show abstract

“…Compared with localized IH lesions, deep lesions are at greater risk of ulceration and dysfunction, and therefore require early and aggressive clinical intervention and treatment ( Cheng and Friedlander, 2016 ). According to the course of disease, IH can be divided into proliferating phase stage, involuting stage and involuted stage ( Yoon et al, 2021 ). Hemangiomas can recede spontaneously, but 90% of IH patients need 9–10 years or more to recede completely ( Darrow et al, 2015 ).…”

Section: Introductionmentioning

confidence: 99%

LncRNA-MCM3AP-AS1 Promotes the Progression of Infantile Hemangiomas by Increasing miR-138-5p/HIF-1α Axis-Regulated Glycolysis

Mei

Xian

Jin

2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Infantile hemangioma (IH) is a common benign tumor of endothelial cells in infants. Most hemangiomas are self-limited, but a few may develop and lead to serious complications that affect the normal life of children. Therefore, finding an effective treatment strategy for IH is a pressing need. Recent studies have demonstrated that non-coding RNAs affect the progression of multiple tumors. This study aims to investigate the mechanism by which LncRNA-MCM3AP-AS1 promotes glycolysis in the pathogenesis of IH. We first documented that the expression of LncRNA MCM3AP-AS1 was significantly upregulated in IH. Furthermore, we demonstrated that MCM3AP-AS1 bound to miR-106b-3p which promotes glycolysis in IH. In addition, we found that inhibition of HIF-1α contributed to the transformation of glycolysis to normal aerobic oxidation, partially reversed the promoting effect on glycolysis by the up-regulation of LncRNA MCM3AP-AS1 in IH disease. More importantly, we demonstrated this phenomenon existed in IH patients. Taken together, we demonstrate that LncRNA-MCM3AP-AS1 promotes the progression of infantile hemangiomas by increasing the glycolysis via regulating miR-138-5p/HIF-1α axis.

show abstract

“…19 Yoon DJ et al expressed that topical timolol may be safe and effective in various dermatological conditions. 20 Chen L et al demonstrated topical timolol in infantile haemangioma and other skin conditions. 21 Baltazard T et al evaluated and supported the safety and benefits of using timolol locally in chronic non-healing venous ulcers.…”

Section: Resultsmentioning

confidence: 99%

Local Application of Timolol 0.5% Solution in Treating Chronic Non-Healing Ulcers – A Prospective Study

Valluru,

Chandana

2023

JFAPS

View full text Add to dashboard Cite

Chronic non-healing ulcers are a variety of ulcers that occur mainly over the lower limb and are resistant to conventional therapy. There are modern treatments like various types of dressings and topical preparations available in the market. However, they are costly and may not be freely available to the general population. Topical usage of β2-AR antagonists like timolol may promote wound healing by enabling keratinocyte migration into the wound to initiate the re-epithelisation. The objective of this study is to assess the effectiveness of topical timolol 0.5% in accelerating the wound healing process by observing the signs of healing. It is a prospective observational study conducted in Government General Hospital, Rangaya Medical Medical College, Kakinada, after getting Institutional Ethical Committee approval from March 2021 to March 2023. One hundred patients with Chronic non-healing foot ulcers were taken for this study. Mean age was 47.64.60% of the study population was in the 20-55 years age group. Reduction in mean ulcer area was on day 15 and day 30 with topical application of timolol.

show abstract

Repurposing Ophthalmologic Timolol for Dermatologic Use: Caveats and Historical Review of Adverse Events

Cited by 8 publications

References 91 publications

The effect of Calcium channel blocker in the Betamethasone-induced Glaucoma model in rabbits

The effect of Calcium channel blocker in the Betamethasone-induced Glaucoma model in rabbits

LncRNA-MCM3AP-AS1 Promotes the Progression of Infantile Hemangiomas by Increasing miR-138-5p/HIF-1α Axis-Regulated Glycolysis

Local Application of Timolol 0.5% Solution in Treating Chronic Non-Healing Ulcers – A Prospective Study

Contact Info

Product

Resources

About